According to a company statement, Pfizer will appeal a decision by the Canadian Federal Court in Toronto denying its application to block approval of Ranbaxy’s generic version of Lipitor. The ruling involves a patent (Canadian Patent No. 2,021,546) covering the calcium salt of atorvastatin, Lipitor’s active ingredient, which expires in July 2010. The ruling on this patent will not have immediate commercial impact as Ranbaxy is subject to other pending patent litigation with Pfizer. T...